CoChat

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

Open access
Lohinai, Zoltan, Hoda, Mir Alireza, Fabian, Katalin, Ostoros, Gyula, Raso, Erzsebet, Barbai, Tamas, Timar, Jozsef, Kovalszky, Ilona, Cserepes, Mihaly, Rozsas, Anita, Laszlo, Viktoria, Grusch, Michael, Berger, Walter, Klepetko, Walter, Moldvay, Judit, Dome, Balazs, Hegedus, Balazs · 2015 · Journal of Thoracic Oncology
Cited by 81

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Introduction: Although classic sensitizing mutations of epidermal growth factor receptor (EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung adenocarcinoma, there are rare EGFR mutations with unknown epidemiology and influence on prognosis and TKI response. Methods: Eight hundred and fourteen lung adenocarcinoma patients with KRAS and/or EGFR mutation analyses for TKI therapy indication were identified. Six hundred and forty-five patients were included in the epidemiological analysis. The clinical outcome was analyzed in 419 advanced-stage patients with follow-up data. Results: Four hundred and eighty (59%) KRAS/EGFR double wild-type, 216 (27%) KRAS mutant, 42 (5%) classic, 49 (6%) rare, and 27 (3%) synonymous EGFR mutant cases were identified. Twenty previously unpublished non-synonymous mutations were found. Rare EGFR mutations were significantly associated with smoking (vs. classic EGFR mutations; p = 0.0062). Classic EGFR mutations but not rare ones were independent predictors of increased overall survival (hazard ratios, 0.45; 95% confidence intervals, 0.25–0.82; p = 0.009). TKI therapy response rate of patients harboring classic EGFR mutations was significantly higher (vs. rare EGFR mutations; 71% vs. 37%; p = 0.039). Patients with classic or sensitizing rare (G719x and L861Q) EGFR mutations had significantly longer progression-free survival when compared with the remaining rare mutation cases (12 vs. 6.2 months; p = 0.048). Conclusions: The majority of rare EGFR mutations was associated with smoking, shorter overall survival, and decreased TKI response when compared with classic EGFR mutations. However, studies characterizing the TKI sensitizing effect of individual rare mutations are indispensable to prevent the exclusion of patients with sensitizing rare EGFR mutations who may benefit from anti-EGFR therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0000000000000492

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 81

Metadata

Authors
Lohinai, Z., Hoda, M. A., Fabian, K., Ostoros, G., Raso, E., Barbai, T., Timar, J., Kovalszky, I., Cserepes, M., Rozsas, A., Laszlo, V., Grusch, M., Berger, W., Klepetko, W., Moldvay, J., Dome, B., & Hegedus, B.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2015-05
Volume
10
Issue
5
Pages
738-746
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2099788868
Cited by
81
References
15
FWCI
8.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1097/jto.0000000000000492
The paper
Lohinai, Z., Hoda, M. A., Fabian, K., Ostoros, G., Raso, E., Barbai, T., Timar, J., Kovalszky, I., Cserepes, M., Rozsas, A., Laszlo, V., Grusch, M., Berger, W., Klepetko, W., Moldvay, J., Dome, B., & Hegedus, B. (2015). Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0000000000000492

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.